Epstein-Barr Virus
8
2
2
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
12.5%
1 terminated out of 8 trials
66.7%
-19.9% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (8)
L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH
R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age
Epstein Barr Virus Infection in Patients With Radiologically Isolated Syndrome
Exploratory Study of EBV DNA Titre Clearance Whilst on Proton Beam Therapy
Graves' Disease Induced by Epstein-Barr Virus Lytic Reactivation
Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement